IO BIOTECH INC. - COMMON STOCK

0,9236

13-февраля-25 15:09:36

15 мин. задержка

Акции

+0,0083

+0,91%

Сегодняшний диапазон

0,9005 - 0,9346

ISIN

N/A

Источник

NASDAQ

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

04 фев 2025 08:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

09 янв 2025 08:05:00 Источник Nasdaq GlobeNewswire
IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

20 дек 2024 08:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

12 ноя 2024 07:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Participation in Upcoming Investor Conferences

11 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

07 ноя 2024 10:00:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting

04 окт 2024 09:00:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

14 сен 2024 02:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

30 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Participation in Upcoming Investor Conferences

26 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

13 авг 2024 07:05:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

25 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire
IO Biotech to Present at Jefferies Global Healthcare Conference

23 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

14 май 2024 07:55:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

24 апр 2024 16:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

15 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

09 апр 2024 12:00:00 Источник Nasdaq GlobeNewswire
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

05 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

06 мар 2024 16:11:01 Источник Nasdaq GlobeNewswire
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

05 мар 2024 16:40:01 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.